Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

Yes — MoCRA (Modernization of Cosmetics Regulation Act of 2022) covers CBD topicals like salves, balms, and lotions. As of July 2025, every facility must register with the FDA, list each product, substantiate safety, and report serious adverse events within 15 business days. Drug-style claims like "pain relief" or "heals eczema" can reclassify a product as an unapproved drug.
As of January 2025, MoCRA represents the most sweeping U.S. federal reform for cosmetics since 1938. All cosmetic products, including CBD topicals like salves, balms, lotions, massage oils, and beauty creams, are subject to:
For the FDA's official resources and the latest guidance, see the FDA's Cosmetics Registration & Listing information.
Failure to register or list products may result in FDA enforcement actions, import alerts, or market withdrawal.
Every facility manufacturing or processing CBD topicals must:
For each CBD topical in commerce as of July 1, 2025, firms must:
Sound complex? CannabisRegulations.ai offers tailored support for navigating and tracking MoCRA requirements.
MoCRA requires that every cosmetic product—CBD-infused or otherwise—must have adequate safety substantiation before marketing. The FDA expects evidence such as:
Firms making "drug-style" claims—such as pain relief, anti-inflammation, or healing—face heightened risk: Product may be considered an unapproved drug, not a cosmetic, risking dual FDA and FTC enforcement.
CBD is NOT automatically a drug or unapproved color additive under MoCRA—but the claims on packaging and marketing are determinative.
See NORML's cannabis product FDA enforcement tracker for recent actions.
All CBD topical product labels distributed in the U.S. after July 1, 2025, must include:
Products labeled with inadequate, incomplete, or misleading information invite regulatory risk and marketplace withdrawal.
If a CBD topical is only for licensed professional use (e.g., massage parlors, esthetic clinics), this must be clearly identified on the outer packaging.
Serious adverse event reporting is now a federal obligation for all cosmetic companies—including those selling CBD topicals. Requirements include:
Learn more about adverse event reporting and how it applies to your business on the FDA website.
The FDA is actively monitoring market compliance—and this includes CBD topicals:
FTC is also aligning with FDA on deceptive or unsubstantiated claims, particularly for CBD-infused products.
Still have questions? CannabisRegulations.ai provides tools, templates, and expert updates to help you navigate MoCRA, FDA, and state-by-state cannabis product obligations.
Stay compliant, stay competitive—make 2025 your year of regulatory clarity.